Hydroxychloroquine sulfate
Brand names: Plaquenil
Hydroxychloroquine sulfate is the salt form supplied in UK tablets of hydroxychloroquine, a disease-modifying antirheumatic drug used for rheumatoid arthritis and lupus erythematosus and as an antimalarial.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It raises lysosomal pH and modulates immune cell function—impairing antigen presentation and Toll-like receptor signalling—to reduce inflammatory activity in autoimmune disease.
Prescribing in practice
- Irreversible retinal maculopathy is the key long-term hazard, so use weight-based dosing, arrange baseline and ongoing retinal screening per Royal College of Ophthalmologists guidance, and report any visual change.
- It may prolong the QT interval and, rarely, cause cardiomyopathy, so use caution alongside other QT-prolonging drugs and in cardiac disease.
- Use caution in G6PD deficiency, hepatic or renal impairment, and psoriasis (which it may worsen).
Monitoring
Perform retinal screening as recommended, watch for visual disturbance, and review cardiac, hepatic and renal status where clinically relevant.
Counselling the patient
- Keep your eye-check appointments and report any blurring or changes in colour vision.
- The benefit builds gradually over weeks to months, so take it consistently.
- Store safely away from children because overdose can be life-threatening.
Evidence & guidelines
Hydroxychloroquine sulfate is the established UK salt form, with efficacy and the retinopathy screening framework documented in the SPC, NICE guidance and Royal College of Ophthalmologists recommendations.
Reference: NICE NG100 (RA); RCOphth/BSR retinopathy screening guidelines; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Cutaneous Lupus Erythematosus · BAD; EULAR
- Osteoporosis / Fragility Fracture · NOGG 2021; NICE NG147; NG224
- Arteritic AION (Giant Cell Arteritis) · RCOphth; BSR
- Osteoarthritis Hip / Knee Management · NICE NG226 (2022)
- Lupus Nephritis · EULAR/ERA-EDTA 2019; KDIGO 2024
- Rheumatoid Arthritis Management · NICE CG79 2018 / EULAR 2022